Physicians' Academy for Cardiovascular Education

Accumulating clinical data on PCSK9 inhibition: What are the key lessons?

Paul M Ridker, MD Harvard Medical School, Boston, USA

Sep. 30, 2015 - ESC 2015 London - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, USA

Video navigation menu

  • The remarkable history of the lipid hypthesis 00:26
  • Why Are Additional Agents Beyond Statins Needed 03:44
  • What Pharmacologic Strategies for LDL Reduction Beyond Statins are Emerging? 05:29
  • PCSK9 Inhibitors: From Target Discovery to Phase III in 10 Years 09:32
  • Why Completing the Phase III Trials Is Crucial 10:55